혈당 조절이 되지 않는 제2형 당뇨병환자에서 로지글리타존과 메트포르민 병합요법의 유효성 (The Efficacy of Fixed Dose Rosiglitazone and Metformin Combination Therapy in Poorly Controlled Subjects with Type 2 Diabetes Mellitus)

서지정보

· 발행기관 : 대한당뇨병학회
· 수록지 정보 : Diabetes and Metabolism Journal / 32권 / 6호 / 506 ~ 512페이지
· 저자명 : 손태서, 이지인, 김인주, 민경완, 손현식

초록

Background: Obese type 2 diabetic subjects are recently increasing in Korea, indicating the importance of
insulin resistance rather than insulin secretory defects in the pathophysioloy of type 2 diabetes. The purpose
of this study is to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy
in poorly controlled subjects with type 2 diabetes mellitus.
Methods: 12 type 2 diabetic subjects who had a HbA1c > 11% or fasting plasma glucose > 15 mmol/L were
included. After a 2 week screening period, the subjected took the fixed does rosiglitazone/metformin for 24
weeks. The treatment with rosiglitazone/metformin began at week 0 with an initial dose of 4 mg/1000 mg
and, unless tolerability issues arose, subjects would be increased to 6 mg/1500 mg at week 4 and at week
8 to the maximum dose of 8 mg/2000 mg. The primary object of this study was to characterize the
magnitude of HbA1c reduction from baseline after 24 weeks of rosiglitazone and metformin treatment in
poorly controlled type 2 diabetics.
Results: The mean age of the subjects was 48.9 ± 10.6 years old, body mass index was 25.0 ± 3.5 kg/m2,
HbA1c was 12.0 ± 1.0%, and fasting plasma glucose was 16.3 ± 3.1 mmol/L. HbA1c was reduced to 7.54
± 1.45% and fasting plasma glucose reduced to 7.96 ± 2.38 mmol/L at week 24. The proportion of HbA1c
responder who showed the reduction from baseline of ≥ 0.7% or HbA1c < 7% was 11 among 12 subjects
(91.7%). 41% of the subjects (5 among 12 subjects) achieved HbA1c level < 7.0% and 75% (9 among 12
subjects) achieved HbA1c level < 8.0%.
Conclusions: In this study, rosiglitazone and metformin combination therapy was effective in glycemic
control in poorly controlled subjects with type 2 diabetes mellitus. (KOREAN DIABETES J 32:506-512, 2008)

영어초록

Background: Obese type 2 diabetic subjects are recently increasing in Korea, indicating the importance of
insulin resistance rather than insulin secretory defects in the pathophysioloy of type 2 diabetes. The purpose
of this study is to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy
in poorly controlled subjects with type 2 diabetes mellitus.
Methods: 12 type 2 diabetic subjects who had a HbA1c > 11% or fasting plasma glucose > 15 mmol/L were
included. After a 2 week screening period, the subjected took the fixed does rosiglitazone/metformin for 24
weeks. The treatment with rosiglitazone/metformin began at week 0 with an initial dose of 4 mg/1000 mg
and, unless tolerability issues arose, subjects would be increased to 6 mg/1500 mg at week 4 and at week
8 to the maximum dose of 8 mg/2000 mg. The primary object of this study was to characterize the
magnitude of HbA1c reduction from baseline after 24 weeks of rosiglitazone and metformin treatment in
poorly controlled type 2 diabetics.
Results: The mean age of the subjects was 48.9 ± 10.6 years old, body mass index was 25.0 ± 3.5 kg/m2,
HbA1c was 12.0 ± 1.0%, and fasting plasma glucose was 16.3 ± 3.1 mmol/L. HbA1c was reduced to 7.54
± 1.45% and fasting plasma glucose reduced to 7.96 ± 2.38 mmol/L at week 24. The proportion of HbA1c
responder who showed the reduction from baseline of ≥ 0.7% or HbA1c < 7% was 11 among 12 subjects
(91.7%). 41% of the subjects (5 among 12 subjects) achieved HbA1c level < 7.0% and 75% (9 among 12
subjects) achieved HbA1c level < 8.0%.
Conclusions: In this study, rosiglitazone and metformin combination therapy was effective in glycemic
control in poorly controlled subjects with type 2 diabetes mellitus. (KOREAN DIABETES J 32:506-512, 2008)

참고자료

· 없음